Bone biomarkers as tools in osteoporosis management

Spine

Volumn 22, Issue 24 SUPPL., 1997, Pages

  Eyre, David R ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biomarkers; Bone resorption; Osteoporosis

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; GLYCOSYLATED PROTEIN; HYDROXYLYSINE; HYDROXYPROLINE; OSTEOCALCIN; PROCOLLAGEN; PYRIDINOLINE; TARTARIC ACID;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; FRACTURE; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK;

EID: 0031408477     PISSN: 03622436     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007632-199712151-00004     Document Type: Review

References (64)

1. Apone S, Lee MY, Eyre DR. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 1997;21:129-36.
2. Atley LM, Mort JS, Lalumiere M, Eyre DR. Quantitative release by cathepsin K of immunoreactive cross-linked N-telopeptides (NTx) from bone type I collagen. J Bone Miner Res 1997;12(Suppl):S417.
3. Beardsworth LJ, Eyre DR, Dickson IR. Changes with age in the urinary excretion of lysyl- and hydroxylysyl-pyridinoline: Two new markers of bone collagen turnover. J Bone Miner Res 1990;5:671-6.
4. Behr W, Barnert J. Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: A simplified method and its clinical plausibility. Clin Chem 1986; 32:1960-6.
5. Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium cross-links of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. Anal Biochem 1988;169:197-203.
6. Bollen A-M, Kiyak HA, Eyre DR. Longitudinal evaluation of a bone resorption marker in elderly subjects. Osteoporos Int 1997;7 (In press).
7. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
8. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
9. Bouman AA, Scheffer PG, Ooms ME, Lips P, Netalenbos C. Two bone alkaline phosphatase assays compared with osteocalcin as a marker of bone formation in health elderly women. Clin Chem 1995;41:196-9.
10. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996;17:333-8.
11. Chesnut CH III, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 102:29-37.
12. Cheung CK, Panesar NS, Haines C, Masarei J, Swaminathan R. Immunoassay of tartrate-resistant acid phosphatase in serum. Clin Chem 1995;41:679-86.
13. Deftos LJ, Wolfert RL, Hill CS. Bone alkaline phosphatase in Paget's disease. Horm Metab Res 1991;23:559-561.
14. Deftos LJ, Wolfert RL, Hill CS, Burton DW. Two-site assays of bone GLA protein (osteocalcin) demonstrate immunochemical heterogeneity of the intact molecule. Clin Chem 1992;38:2318-21.
15. Delmas PD. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 1992;13:517-21.
16. Delmas PD, Demiaux B, Malaval L, Chapuy MC, Meunier PJ. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif Tissue Int 1986;38: 60-61.
17. Demers LM, Kleerekoper M. Recent advances in biochemical markers of bone turnover (editorial). Clin Chem 1994;40: 1994-5.
18. Diaz-Diego EM, Diaz-Martin MA, de la Piedra C, Rapado A. Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women. Horm Metab Res 1995;27: 151-4.
19. Drake FH, Dodds RA, James IE, et al. Cathepsin K, but not cathepsin B, L or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996;271:12511-6.
20. Ebeling PR, Peterson JM, Riggs BL. Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992;7:1243-50.
21. Ebeling PR, Atley LM, Guthrie JR, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366-71.
22. Ek-Rylander B, Flores M, Wendel M, Heinegård D, Andersson G. Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1994;269:14853-6.
23. Eriksen EF, Brixen K, Charles P. New markers of bone metabolism: Clinical use in metabolic bone disease. Eur J Endocrinol 1995;132:251-63.
24. Eyre DR. Collagen cross-linking amino acids. Methods Enzymol 1987;144:115-39.
25. Eyre DR. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand Suppl 1995;266:166-70.
26. Eyre DR, Van Ness K, Koob TJ. Quantitation of hydroxy-pyridinium crosslinks in collagen by high performance liquid chromatography. Anal Biochem 1984;137:380-8.
27. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Miner Res 1995;10:641-9.
28. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;79:780-5.
29. Garnero P, Grimaux M, Demiaux B, Preaudat C, Seguin P, Delmas PD. Measurement of serum osteocalcin with a human specific two-site immunoradiometric method. J Bone Miner Res 1992;7:1389-98.
30. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
31. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11: 337-49.
32. Garnero P, Hausherr E, Chapuy M-C, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 1996;11: 1531-8.
33. Gertz BJ, Shao P, Hanson DA, et al. Monitoring bone resorption in early post-menopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994;9:135-42.
34. Gundberg CM, Lian JB, Gallop PM, Steinberg JJ. Urinary g-carboxyglutamic acid and serum osteocalcin as bone markers: Studies in osteoporosis and Paget's disease. J Clin Endocrinol Metab 1983;57:1221-25.
35. Hanson DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J Biol Chem 1996;271:26508-16.
36. Hanson DA, Weis M-AE, Bollen A-M, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
37. Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporos Int 1993;3:50-2.
38. Hattersley G, Chambers TJ. Generation of osteoclastic function in mouse bone marrow cultures: Multinuclearity and tartrate-resistant acid phosphatase are unreliable markers for osteoclastic differentiation. Endocrinology 1989;124:1689-96.
39. Hill C, Wolfert RL. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 1990;186:315-20.
40. Kraenzlin MD, Mohan S, Singer F, et al. Development of a radioimmunoassay for the N-terminal type I procollagen: Potential use to assess bone formation (abstract). Eur J Clin Invest 1989;19:A86.
41. Kraenzlin ME, Lau KHW, Liang L, et al. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 1990;71: 442-51.
42. Lau KHW, Orishi T, Wergedal JE, Singer FR, Baylink DJ. Characterization and assay of tartrate-resistant acid phosphatase activity in serum: Potential use to assess bone resorption. Clin Chem 1987;33:458-62.
43. Melton LJ, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-91.
44. Moro L, Gazzarini C, Crivellari D, Galligioni E, Talamini R, de Bernard B. Biochemical markers for detecting bone metastases in patients with breast cancer. Clin Chem 1993;39:131-4.
45. Moro L, Modricky C, Stagni N, Vittur F, de Bernard B. High-performance liquid chromatographic analysis of urinary hydroxylysyl glycosides as indicators of collagen turnover. Analyst 1984;109:1621-2.
46. Panigrahi K, Delmas PD, Singer F, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem 1994;40:822-8.
47. Parfitt AM, Simon LS, Villanueva AR, Krane SM. Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone: Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Miner Res 1987;2:427-36.
48. Pavori R, DeVecchi E, Fermo I, et al. Total urinary hydroxyproline determined with rapid and simple high-performance liquid chromatography. Clin Chem 1992;38:407-11.
49. Price PA, Nishimoto SK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 1980;77:2234-8.
50. Prior JC, Vigna YM, Wark JD, et al. Premenopausal ovanectomy-related bone loss: A randomized, double-blind one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997;12 (In press).
51. Prestwood KM, Pilbeam CC, Burleson JA, et al. The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 1994;79:366-71.
52. Riggs BL, Melton LJ III, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996;18(Suppl):197S-201S.
53. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radio-immunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new marker of bone degradation. Clin Chem 1993;39:635-40.
54. Risteli J, Risteli L. Assays of type procollagen domains and collagen fragments: Problems to be solved and future trends. Scand J Clin Lab Invest 1997;57(Suppl):105-13.
55. Robins SP. An enzyme-linked immunoassay for the collagen cross-link pyridinoline. Biochem J 1982;207:617-20.
56. Robins SP, Stewart P, Astbury C, Bird HA. Measurement of the cross-linking compound, pyridinoline, in urine as an index of collagen degradation. Ann Rheum Dis 1986;45:969-73.
57. Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel M. Direct enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
58. Rosen CJ, Chesnut CH III, Mallinak NJS. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
59. Rosen HN, Dresner-Pollak R, Moses AC, et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994; 54:26-9.
60. Schneider DL, Barrett-Connor EL. Urinary N-telopeptide levels discriminate normal, osteopenic and osteoporotic bone mineral density. Arch Intern Med 1997;157:1241-5.
61. Segrest JP, Cunningham LW. Variation in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism. J Clin Invest 1970;49:1497-509.
62. Seibel MJ, Robins SP, Bilezikian JP. Urinary pyridinium cross-links of collagen: Specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992;3: 263-70.
63. Seyedin SM, Kung VT, Daniloff YN, et al. Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Miner Res 1993;8:635-41.
64. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. Clin Endocrinol Metab 1991;72:367-73.